SONN icon

Sonnet BioTherapeutics
SONN

Overview Fund Activity

2 hedge funds and large institutions have $2.97K invested in Sonnet BioTherapeutics in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 9 closing their positions.

Holders
2
Holders Change
-9
Holders Change %
-81.82%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

1
AC
1
Armistice Capital
New York
$0
2
SM
2
Sabby Management
Florida
$0
3
TRCT
3
Tower Research Capital (TRC)
New York
$2.53K
4
VF
4
Virtu Financial
New York
$0
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$0
Name Market Value Shares Shares
Change 		Shares
Change %
TRCT
1
Tower Research Capital (TRC)
New York
$2.53K 378 -6,793 -95%
BlackRock
2
BlackRock
New York
$435 65 -455 -88%
PWMG
3
Private Wealth Management Group
New Jersey
– – -3 Closed
AC
4
Armistice Capital
New York
– – -272,000 Closed
SM
5
Sabby Management
Florida
– – -238,395 Closed
VF
6
Virtu Financial
New York
– – -32,687 Closed
Geode Capital Management
7
Geode Capital Management
Massachusetts
– – -16,704 Closed
Vanguard Group
8
Vanguard Group
Pennsylvania
– – -14,726 Closed
UBS Group
9
UBS Group
Switzerland
– – -3,997 Closed
Bank of America
10
Bank of America
North Carolina
– – -28 Closed
Morgan Stanley
11
Morgan Stanley
New York
– – -4 Closed
CFGS
12
Concourse Financial Group Securities
Alabama
– – – –